APOE‐ε4 carriership and dementia risk over 10 years among Asian American and White older adults

by Clinical Neuropsychologist Online | Friday, July 10, 2026 | Dementia

Abstract INTRODUCTION The Apolipoprotein E ε4 allele (APOE-ε4) is a well-established dementia risk factor among non-Latino White individuals but remains understudied among Asian Americans. We estimated its association with dementia risk among Chinese, Japanese,...

Glutamate carboxypeptidase II activation in astrocytes mediates glymphatic impairment and cognitive vulnerability in the aging brain following surgery

by Clinical Neuropsychologist Online | Friday, July 10, 2026 | Dementia

Abstract INTRODUCTION Perioperative neurocognitive disorder is a common and debilitating complication in the elderly, yet its cellular and molecular mechanisms in the aging brain remain poorly understood. METHODS Using aged mice, we examined the impact of abdominal...

Understanding the Experiences of Family Caregivers of Persons Living With Dementia Participating in an ‘Overnight’ Adult Day Program

by Clinical Neuropsychologist Online | Thursday, July 9, 2026 | Dementia

Dementia, Ahead of Print. Family caregivers of persons with dementia often face chronic stress, disrupted sleep, and emotional exhaustion. While adult day programs provide daytime respite, support during nighttime, when caregiving responsibilities can intensify,...

Modular brain networks shape amyloid‐driven tau spread and cognitive decline

by Clinical Neuropsychologist Online | Thursday, July 9, 2026 | Dementia

Abstract INTRODUCTION Alzheimer’s disease involves trans-synaptic spread of tau pathology from temporal lobe epicenters, driven by amyloid beta (Aβ) deposition. How modular brain network architecture shapes this process and the ensuing cognitive decline remains...

Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer’s disease

by Clinical Neuropsychologist Online | Thursday, July 9, 2026 | Dementia

Abstract INTRODUCTION Lecanemab, the first disease-modifying therapy for Alzheimer’s disease (AD), mitigates pathology primarily by clearing amyloid plaques, but its impact on peripheral immunity remains unclear. METHODS To assess Lecanemab’s immunological...

Multicenter validation of plasma p‐tau217/ amyloid beta 1‐42 ratio in symptomatic Alzheimer’s disease

by Clinical Neuropsychologist Online | Thursday, July 9, 2026 | Dementia

Abstract INTRODUCTION This study evaluated the diagnostic performance of the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio to detect amyloid positivity in patients with cognitive decline symptoms. METHODS The Lumipulse Plasma Ratio was evaluated using...